Nm23-H1及hTERT在子宮頸癌之表現

Human nonmetastatic clone 23 (nm23-H1)和human telomerase reverse transcriptase (hTERT) 於高度子宮頸細胞內贅瘤 (high-grade cervical intraepithelial neoplasia) 及侵入性子宮頸癌 (invasive cervical cancer) 組織切片之免疫組織化學表現有增強趨勢，但是hTERT 免疫組織化學表現和子宮頸癌臨床病理特徵似乎較沒有關係，而nm23-H1 和子宮頸癌臨床病理特徵及預後存活似乎較有關係。我們因而以子宮頸組織晶片，研究nm23-H1免疫組織化學染色之表現，檢驗nm23-H1 蛋白表現和病人子宮頸癌臨床病理特徵、復發及預後存活之關係。我們並以real time polymerase chain reaction 驗證，於子宮頸癌組織，nm23-H1 之mRNA 表現較其周邊正常組織對照組強。我們進一步發現，nm23-H1 免疫蛋白之表現和子宮頸癌基質侵犯深度 (P = 0.003) 、腫瘤大小 (P = 0.044) 及細胞分化 (P = 0.025) 有關，且nm23-H1 免疫化學染色強的子宮頸癌病人預後較差。

Human nonmetastatic clone 23 (nm23-H1) and human telomerase reversetranscriptase (hTERT) may be separately involved in tumor progression ofuterine cervix. Moreover, we found normal cervix and cervical low-gradeintraepithelial neoplsia (low-grade CIN) samples had concurrent low expressionof hTERT and nm23-H1, whereas high-grade CIN [CIN2 (moderate dysplasia)and CIN3 (severe dysplasia, carcinoma in situ)] SCC samples had concurrenthigh immunoreactivity. However, hTERT immunoreactivity seemed to have nosignificant association with clinicopathological variables of cervical cancer. Onthe contrary, only deep stromal invasion was significantly associated with highnm23-H1 immunoreactivity based on our limited cervical tissue samples. A highcumulative recurrence hazard was demonstrated for the high nm23-H1expression group. Therefore, using real time polymerase chain reaction andtissue microarray of cervical samples, we further demonstrated that nm23-H1mRNA expression and H score (median H scores: 2.0 vs. 0.3, P = 0.001) werehigher in cervical cancer tissues than normal counterparts, respectively.Nm23-H1 expression was significantly associated with depth of stromalinvasion (P = 0.003), tumor diameter (P = 0.044) and cell differentiation (P =0.025). Furthermore, positive nm23-H1 expression was significantly associatedwith poor overall survival.